Inside Innovation

Washington remains a top life science cluster with exciting and innovative news from companies across the state. Whether it’s a record-breaking deal with Pfizer acquiring

As the global pharmaceutical market is expected to reach over $1.5 trillion by the end of 2023, life sciences is entering a new era of

The Fred Hutchinson Cancer Center revealed a $320 million clinic expansion in South Lake Union to fuel continued growth and work in cancer breakthroughs. The

After Pfizer’s $43 billion plan to buy Bothell, Wash.-based biotech giant, Seagen, Seattle-area biotech experts believe that Seagen’s technology and talent will be a great

In a $43 billion deal, Pfizer will acquire Bothell-based biotech Seagen, expected to be completed in late 2023 or early 2024. Pfizer intends to maintain

CBRE’s recent report for Q4 2022 shows promise for the future of Seattle’s life science industry. The region recorded its highest fourth-quarter capital funding on

Moderna wants to tap Seattle’s pool of talent, the Cambridge, Massachusetts-based company announced last week. It is opening an office on April 4 with plans

At the 2023 UW Medical Data Science Symposium the University of Washington launched a new hub named the Institute for Medical Data Science. The new

In a dynamic interview with Osmosis Raise the Line podcast, Marc Cummings, president & CEO of Life Science Washington, and Dr. Tina Albertson, chief medical officer

A new report from CBRE shows that the life sciences real estate market began to normalize in the fourth quarter, with rebounding numbers in venture

Seattle-based biotech Monod Bio has licensed a new luciferase technology (LuxSit), which is a de novo enzyme luciferase technology. The technology comes from the lab

Newsweek and global research and data firm Statista announced the fourth-annual ranking of the 500 most responsible companies regarding ESG (environment, social and corporate governance)